Trials / Recruiting
RecruitingNCT06785012
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants With Major Depressive Disorder (MDD)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-89495120 | JNJ-89495120 will be administered. |
| DRUG | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2024-12-26
- Primary completion
- 2026-06-26
- Completion
- 2026-06-26
- First posted
- 2025-01-20
- Last updated
- 2026-04-13
Locations
44 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06785012. Inclusion in this directory is not an endorsement.